Strides Pharma US facility gets clean USFDA closure report

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹876.00

prior close

₹869.40

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.0%-0.0% vs market

Pharmaceuticals peers, median of 157sector-0.5%-0.5% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.9

10m

+1.3

15m

+0.4

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-1.0-0.0-0.5-0.5

Next day

-1.3-1.8+0.5-1.2-0.1

+0.6+0.8-0.2+0.5+0.0

+0.2+1.8-1.5+1.0-0.8

+0.0+1.2-1.2+0.9-0.9

-1.0+0.7-1.8+0.1-1.1

-1.9-1.5-0.5-1.4-0.6

15d

-1.8-2.5+0.6-2.9+1.1

-3.2-7.2+4.0-5.1+1.9

+11.6-8.9+20.5-7.4+19.0

+20.5+5.5+15.1+0.2+20.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Strides Pharma's US step-down subsidiary received a USFDA Establishment Inspection Report (EIR) for its Chestnut Ridge, New York formulations facility. The Dec 17-23, 2025 inspection was classified as Voluntary Action Indicated, meaning no further action needed. It included a pre-approval inspection for drug-device combinations covering nasal sprays. Facility makes liquids, gels, hormones, and controlled substances for the US market.

Likely market impact

Positive regulatory outcome; strengthens US business and near-term growth, particularly in nasal sprays and drug-device combinations.